Clinical Trials Directory

Trials / Unknown

UnknownNCT03530761

Korean Cohort Study of AKI & HRS in Cirrhosis

Kidney Biomarkers for the Prediction of Response to Terlipressin and Survival in Cirrhotic Patients With Acute Kidney Injury: Multicenter, Prospective Cohort Study

Status
Unknown
Phase
Study type
Observational
Enrollment
245 (estimated)
Sponsor
Soonchunhyang University Hospital · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to investigate i) whether two biomarkers (urine NAG, urinary cystatin C) could be predictive factor in patient with liver cirrhosis, , and ii) whether these biomarkers can predict response of terlipressin.

Detailed description

Acute kidney injury (AKI) in patients with liver cirrhosis is sometimes accompanied by tubular injury which can lead to poor outcome. Current AKI criteria using serum creatinine (Cr) has some limitations to predict reversibility of renal function and discriminate renal parenchymal injury in cirrhotic patients. The aim of this study is to evaluate whether urine biomarkers \[cystatin C, N-acetyl-β-D-Glucosaminidase (NAG)\] can predict survival and response to terlipressin in cirrhotic patients with AKI.

Conditions

Timeline

Start date
2017-08-01
Primary completion
2018-12-31
Completion
2019-12-31
First posted
2018-05-21
Last updated
2018-05-21

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT03530761. Inclusion in this directory is not an endorsement.